Back to top

Image: Bigstock

J&J to Acquire Ollin Biosciences: A Look at Its Recent Buyouts

Read MoreHide Full Article

Key Takeaways

  • J&J agreed to acquire Ollin Biosciences for $2.2 billion upfront, expanding its ophthalmology pipeline.
  • OLN324 targets retinal diseases, with Blackstone providing $750 million to fund its phase III development.
  • Acquisitions of Firefly, Intra-Cellular, Shockwave and Abiomed strengthen J&J's pipeline and MedTech growth.

Johnson & Johnson (JNJ - Free Report) has been actively pursuing strategic acquisitions to strengthen its Innovative Medicine and MedTech businesses, diversify its portfolio and accelerate long-term revenue growth. The company has been increasingly focused on acquiring promising drug candidates, innovative technology platforms and high-growth medical device businesses to expand its presence in lucrative therapeutic markets.

Ollin Biosciences Buyout Expands JNJ's Ophthalmology Pipeline

Earlier this week, J&J announced a definitive agreement to acquire clinical-stage biotechnology company Ollin Biosciences for $2.2 billion upfront, with potential additional regulatory and commercial milestone payments of approximately $1.125 billion. The acquisition will add OLN324, an investigational phase III bispecific antibody being developed for retinal diseases, including wet age-related macular degeneration and diabetic macular edema. OLN324 targets VEGF and Ang2 pathways and has the potential to improve retinal fluid control and extend treatment intervals. The transaction, expected to close by the end of 2026, will strengthen J&J’s ophthalmology pipeline and complement its established presence in vision care.

As part of the transaction, J&J will also enter into a separate development funding agreement with Blackstone Life Sciences, under which Blackstone will provide $750 million over multiple years to fully fund OLN324's phase III development, in exchange for potential milestone payments and royalties.

Recent Acquisitions Boost JNJ's Oncology & Neuroscience Portfolios

J&J has undertaken several other strategic acquisitions over the past two years to strengthen its drug pipeline. In July 2026, the company completed the $1 billion acquisition of California-based biotech, Firefly Bio, adding its proprietary Firelink degrader antibody conjugate platform, which is being developed to target KRAS-driven and other difficult-to-treat cancers.

In 2025, J&J invested more than $32 billion in R&D and M&A, including the acquisitions of Intra-Cellular Therapies and Halda Therapeutics. The acquisition of Intra-Cellular Therapies added Caplyta, an atypical antipsychotic, to its neuroscience portfolio, which is approved for the treatment of schizophrenia, bipolar I and II depression, and major depressive disorder. The acquisition has already contributed meaningfully to J&J’s revenue growth, with Caplyta generating $1.03 billion in sales in the first nine months of 2026. With the Halda Therapeutics acquisition, J&J gained access to its novel RIPTAC technology platform and lead prostate cancer candidate, JNJ-6143 (formerly HLD-0915).

JNJ's Past Acquisitions Have Boosted MedTech Growth

J&J’s acquisitions have played an important role in expanding its MedTech business, particularly in cardiovascular care. In May 2024, J&J acquired Shockwave Medical, which strengthened its position in the highest-growth, innovation-oriented segments of cardiovascular intervention. In December 2022, the company acquired Abiomed, gaining its Impella heart pump portfolio and strengthening its presence in the high-growth heart recovery market. The benefits of these acquisitions are increasingly evident in J&J’s financial performance. Shockwave has emerged as an important growth driver, recording 17% growth in the third quarter of 2026, supported by continued adoption of its intravascular lithotripsy platforms. Abiomed has also contributed to cardiovascular sales growth over the past few years.

Acquisitions Support J&J's Long-Term Growth Strategy

Strategic acquisitions have been instrumental in strengthening J&J’s diversified business model and creating additional growth opportunities. While acquisitions like Intra-Cellular Therapies, Shockwave Medical and Abiomed have already contributed to commercial sales, more recent transactions involving Ollin Biosciences, Firefly Bio and Halda Therapeutics are aimed at expanding J&J’s pipeline and supporting future product launches. Meanwhile, acquisitions in cardiovascular devices have enhanced its exposure to higher-growth MedTech categories. These strategic investments, alongside internally developed products, should support revenue growth over the coming years.

Big Pharma's Acquisition Spree Continues in 2026

Several major drugmakers like AbbVie (ABBV - Free Report) , Gilead (GILD - Free Report) , Eli Lilly (LLY - Free Report) , Merck and GSK have pursued strategic acquisitions in 2026 to strengthen their pipelines and expand into high-growth therapeutic areas.

AbbVie acquired Apogee Therapeutics for approximately $10.9 billion to bolster its immunology portfolio, while GSK acquired Nuvalent for approximately $10.6 billion to expand its oncology pipeline. Gilead Sciences acquired Arcellx for approximately $7.8 billion to strengthen its presence in cell therapies for multiple myeloma. Eli Lilly also acquired Centessa Pharmaceuticals in a deal valued at up to $7.8 billion to expand its neuroscience pipeline, while Merck acquired Terns Pharmaceuticals for approximately $6.7 billion to bolster its oncology portfolio.

JNJ’s Price Performance, Valuation and Estimates

J&J’s shares have outperformed the industry so far this year. The stock has risen 36.7% this year compared with 26.6% appreciation of the industry. 

Zacks Investment ResearchImage Source: Zacks Investment Research

From a valuation standpoint, J&J is slightly expensive. Going by the price/earnings ratio, the company’s shares currently trade at 24.55 forward earnings, higher than 19.88 for the industry. The stock is also trading above its five-year mean of 15.65.

Zacks Investment ResearchImage Source: Zacks Investment Research

The Zacks Consensus Estimate for 2026 earnings has declined from $11.17 to $11.12 over the past 30 days, while that for 2027 earnings has declined from $12.02 per share to $11.56 over the same time frame.

Zacks Investment ResearchImage Source: Zacks Investment Research

J&J has a Zacks Rank #3 (Hold) at present.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Published in